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Genetic mutations of SHANK3 have been reported in patients with intellectual disability,
autism spectrum disorder (ASD) and schizophrenia. At the synapse, Shank3/ProSAP2 is a
scaffolding protein that connects glutamate receptors to the actin cytoskeleton via a chain of
intermediary elements. Although genetic studies have repeatedly confirmed the association of
SHANK3 mutations with susceptibility to psychiatric disorders, very little is known about the
neuronal consequences of these mutations. Here, we report the functional effects of two
de novo mutations (STOP and Q321R) and two inherited variations (R12C and R300C)
identified in patients with ASD. We show that Shank3 is located at the tip of actin filaments and
enhances its polymerization. Shank3 also participates in growth cone motility in developing
neurons. The truncating mutation (STOP) strongly affects the development and morphology of
dendritic spines, reduces synaptic transmission in mature neurons and also inhibits the effect
of Shank3 on growth cone motility. The de novo mutation in the ankyrin domain (Q321R)
modifies the roles of Shank3 in spine induction and morphology, and actin accumulation in
spines and affects growth cone motility. Finally, the two inherited mutations (R12C and R300C)
have intermediate effects on spine density and synaptic transmission. Therefore, although
inherited by healthy parents, the functional effects of these mutations strongly suggest that
they could represent risk factors for ASD. Altogether, these data provide new insights into the
synaptic alterations caused by SHANK3 mutations in humans and provide a robust cellular
readout for the development of knowledge-based therapies.
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Introduction
Autism spectrum disorders (ASDs) are heterogeneous
neurodevelopmental disorders diagnosed on the basis
of three behaviorally altered domains: social deficits,
impaired language and communication and stereo-
typed behaviors. ASD affect 1% of the population,
with males being affected four times more often than
females.
1–3 Family and twin studies indicate a strong
genetic basis for ASD, but the mechanisms of
transmission remain largely unknown. Recently,
several synaptic genes have been associated with
ASD, providing a better idea of the pathways
involved.
4 The 22q13 deletion syndrome is character-
ized by developmental delay, moderate to profound
language delay, delay/absence of expressive speech,
hypotonia and autistic features that are caused by the
loss of the SHANK3 gene located at the tip of this
chromosome.
5 The SHANK3 gene can also be altered
in patients with ASD, and recently, we have shown
that mutations, or the loss of one copy of SHANK3,a r e
associated with autism, whereas the presence of an
extra copy of SHANK3 might be associated with
Asperger syndrome.
6 The variations identified
included de novo deleterious mutations and inherited
non-synonymous variations affecting highly conserved
amino acids in the ankyrin domain.
6,7 Although these
mutations were inherited from healthy parents, they
could contribute to the disorder in combination with
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tion with other mutated genes.
The three members of the Shank family (Shank1, 2
and 3) are core components of the postsynaptic
density, a highly organized cytoskeletal structure
found adjacent to the postsynaptic membrane of
excitatory synapses. Shank proteins have ankyrin
repeats at their N terminus, followed by a SH3 (Src
homology) domain, a PDZ (postsynaptic density
95/discs large/zona occludens-1 homology) domain,
a proline-rich region and a SAM (sterile alpha motif)
domain at their C-terminal region.
8–10 All of these
domains are involved in protein–protein interactions,
linking different glutamate receptors, scaffolding
proteins and intracellular effectors to the actin
cytoskeleton. Indeed, Shank proteins are associated
with NMDA (N-methyl-D-aspartate) receptors via the
guanylate kinase-associated protein (GKAP)/postsy-
naptic density-95 (PSD-95) complex and with type I
metabotropic glutamate receptors via Homer in the
proline-rich domain.
8,11,12 In addition, Shank proteins
can bind to several actin-regulatory molecules, such
as cortactin,
13,14 Sharpin,
15 a-fodrin,
16 Abp1,
17 b-Pix
18
and SPAR.
19 The actin cytoskeleton of the dendritic
spine is particularly dynamic and has a pivotal role in
the formation and the maturation of spines and is also
involved in the morphological changes that occur in
spines during synaptic plasticity.
20 Thus, Shank
proteins and their binding partners are involved
in vitro in the regulation of the size and the shape of
dendritic spine.
21–23
To further assess the functional consequences of
SHANK3 mutations, we used an overexpression
approach in cultured neurons to investigate the
molecular mechanisms modulated by Shank3 in
synapse formation and axonal outgrowth. We first
examined the subcellular localization of the wild-type
and mutated Shank3 proteins in fibroblasts and
embryonic primary neuronal cultures. Our results
show that the truncating mutation strongly affected
spine development and morphology, as well as
growth cone motility, whereas the de novo mutation
Q321R preferentially had an effect in early stages of
development. Finally, inherited mutations (R12C and
R300C) displayed an intermediate phenotype, with
lowered spine induction and maturation, and growth
cone motility compared with wild-type Shank3.
Materials and methods
DNA constructs
Full-length rat Shank3 complementary DNA has been
used previously.
6 Mutated forms (green fluorescent
protein GFP–Shank3
R12C, GFP–Shank3
R300C and GFP–
Shank3
Q321R) of GFP–Shank3 were generated using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA). Deletion variants of GFP–Shank3
STOP
were made by introducing a STOP codon by direct
mutagenesis to generate Shank3 mutants lacking the
C-terminal part of the protein, corresponding to the
mutation frameshift 3915 identified in patients. The
monomeric red fluorescent protein (monomeric RFP)
construct was generously provided by I Macara
(University of Virginia, Charlottesville, VA, USA).
C Gauthier-Rouviere (Centre de Recherche en Biochimie
Macromole ´culaire, Centre National de la Recherche
Scientifique Montpellier, France) generously pro-
vided the RFP–actin construct. The SureSilencing
short-hairpin RNA plasmids cloned in p-RFP-C-RS
were purchased from Origene (Rockville, MD, USA).
Details of the downregulation experiments are
described in the supplementary note.
Antibodies
Primary antibodies were anti-actin (Cytoskeleton Inc.,
Denver, CO, USA), anti-b-tubulin (Tuj-1, Covance,
Princeton, NJ, USA), anti-MAP2 (Chemicon, Temecula,
CA, USA), anti-DsRED (Clontech, Palo Alto, CA, USA),
anti-GFP (Invitrogen, Carlsbad, CA, USA), anti-phospho-
paxillin (Cell Signalling, Danvers, MA, USA), anti-
Shank3 (NeuroMab Facility, Davis, CA, USA), anti-
cortactin and anti-vinculin (Sigma-Aldrich, St Louis,
MO, USA). Alexa Fluor 546 and 647 phalloidin were
used to stain F-actin (Invitrogen). Secondary anti-
bodies were conjugated to Alexa Fluor 488, 546 and
647 (Invitrogen).
Cell culture and transfection
HEK293T and COS-7 cells used for transient transfec-
tion were maintained in Dulbecco0s modied Eagle0s
medium supplemented with fetal calf serum and
antibiotics. Cells were transfected using calcium
phosphate, as previously described.
24 Hippocampal
neuronal cultures were prepared and transfected with
the different constructs using the calcium phosphate
method.
24,25
Immunocytochemistry
After 4 days, cells were fixed with 4% paraformal-
dehyde (PFA), washed, permeabilized with 0.1%.
Triton/phosphate-buffered saline (PBS) or 0.05% sapo-
nin/PBS, blocked for 1h with 10% normal goat serum
(NGS) or 3% bovine serum albumin (BSA) before
incubating for 1.5h with primary antibodies at room
temperature in 3% NGS/PBS or in 0.2% BSA/PBS,
then washed in PBS and incubated with secondary
antibodies in 3% NGS/PBS or in 0.2% BSA/PBS. Then,
phalloidin was incubated for 1h in 0.2% BSA/PBS.
Protein, western blots, immunoprecipitation
Protein preparation, western blots and immunopreci-
pitation were performed, as described,
26 and detailed
in the supplementary note.
Ratio of F- to G-actin
The amount of F-actin and G-actin was measured
with an Actin Polymerization Assay kit (BK037-
Cytoskeleton). HEK293T cells were co-transfected
with RFP–actin and GFP–C3 (control) or GFP–
Shank3
WT or GFP–Shank3
STOP. Two days after trans-
fection, the cells were resuspended in F-actin stabi-
lization buffer with adenosine triphosphate (1mM)
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experiments were performed at 371C. F-actin was
pelleted by a 1-hr centrifugation at 100000 g, and
the supernatant (G-actin) was separated. The pellet
was resuspended in the same volume as the super-
natant using ice-cold Milli-Q water and 10mM
cytochalasin D for 2h at 41C. Actin was quanti-
fied by western blot using an anti-actin antibody
(Cytoskeleton). The ratio of F-actin to G-actin was
determined using an Odyssey infrared imaging
system (LI-COR Biosciences, Nebraska, USA).
Microscopy and quantitative analyses of spine
morphology
Confocal images were acquired with a Leica DMR
TCS SP2 AOBS confocal microscope (Leica, France),
using the 60  objective. Each image was a z-series
projection taken at 0.02-mm-deep intervals. The
morphometric measurements (width and length of
spine) were made using Volocity analysis software
(PerkinElmer, MA, USA). Each experiment was
performed on five to seven independent neuronal
preparations. Cells were co-transfected with mono-
meric RFP to visualize detailed morphology and to
outline the spines. To determine spine size, 1500–
1800 spines (from 16–28 neurons) were measured for
each condition. For spine length, the distance from
the base of the neck to the spine head was measured,
and for spine width, the maximal width of the spine
head perpendicular to the length was measured. To
determine spine density, 10 regions of 20mm were
averaged per neuron.
To quantify F-actin and cortactin in spines,
immunofluorescence images were acquired on a
DM6000 Leica microscope equipped with MetaMorph
software (Molecular devices, Sunnyvale, CA, USA).
The fluorescence intensity of F-actin or cortactin was
measured as the average intensity in the manually
area-represented head of the spine. Each experiment
was performed on four to six independent neuronal
preparations, and 20–38 neurons were measured for
each condition.
Electrophysiology
Neurons (DIV17) co-transfected with GFP and the
plasmids of interest were selected based on their
fluorescence, and miniature excitatory synaptic
current (mEPSC) were recorded, as previously
published.
22 Briefly, the recording pipettes had a
resistance of 5–10MW when filled with the following
medium (in mM): 140 CsCl, 0.5 CaCl2, 20 EGTA,
10 HEPES, 10 D-glucose, pH 7.2 and osmolarity of
300mOsm. The high concentration of EGTA avoided
slow Ca
2þ-dependent desensitization of NMDARs.
27
Neurons were perfused continuously with the following
external medium (in mM): 140 NaCl, 2 CaCl2,
3 KCl, 10 HEPES, 10 D-glucose, 0.01 glycine, 0.01
bicuculline, 0.0003 tetrodotoxin, pH 7.4 and
osmolarity of 330mOsm.
Live imaging
Four days after transfection, growth cones of
neurons transfected at DIV2 were analyzed by
imaging every 2s for 10min with an Olympus IX71
inverted microscope (Olympus, France) using a
60  oil immersion objective (n=35–67 growth cones
from five independent experiments). The growth
cone motility index was calculated, as previously
described.
28
Statistical significance
Data are shown as the mean±s.e.m. The statistical
significance of the results was analyzed using one-
way analysis of variance in all experiments. For
electrophysiological studies, we used the non-para-
metric Kruskal–Wallis test for more than two inde-
pendent small samples.
Results
One of the aims of this study was to evaluate the
contribution of Shank3 gene mutations to the actin
dynamics-dependent formation of dendritic spines.
For this purpose, we studied SHANK3 mutations
identified in patients with ASD.
6,7 Among these
mutations (Figure 1a), one is a frameshift mutation
at position 3680 in human SHANK3 complementary
DNA (3915 in rat), which introduces a premature
STOP codon at position 1227 in humans (1304 in rat),
leading to a truncated form of Shank3 (Shank3
STOP).
The remaining three mutations are non-synonymous
mutations located in or near the highly conserved
ankyrin domain (R12C, R300C and Q321R, referred to
as Shank3
R12C, Shank3
R300C and Shank3
Q321R, respec-
tively).
6,7 An immunoblot analysis of the different
constructs revealed that the fusion proteins carrying
the point mutations Shank3
R12C, Shank3
R300C and
Shank3
Q321R had similar levels of expression and size
as the GFP–Shank3
WT, whereas the frameshift muta-
tion (Shank3
STOP) led to a shorter protein (Figure 1b).
Decreased clustering of mutated Shank3 at the tips of
actin filaments
We first analyzed the intracellular localization of
Shank3
WT in COS-7 cells (Figure 1c). Shank3
WT was
found at the plasma membrane and in large intracel-
lular clusters, as previously reported in HEK cells.
29
Interestingly, we noticed that Shank3 clustered at the
tips of actin filaments and colocalized with vinculin
or phospho-paxillin, two focal adhesion proteins
(Figure 1c). Overexpression of Shank3
R12C,
Shank3
R300C and Shank3
Q321R in COS-7 showed that
mutations in the ankyrin domain did not affect the
localization of Shank3 at the membrane or in
intracellular clusters (Figure 1d). However, the dis-
tribution of Shank3
STOP was restricted to small
aggregates around the nucleus, suggesting that the
lack of the C terminus in Shank3 affected its targeting
and its interaction with the actin cytoskeleton in
COS-7 cells. The analysis of the colocalization of
Shank3 with actin stress fibers showed that
SHANK3 mutations in autism and spine morphology
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Molecular Psychiatry60±2% of actin filaments per cell had clusters of
Shank3
WT. Mutations in the ankyrin domain
(R12C, R300C and Q321R) significantly reduced this
localization of Shank3 (43±3% for Shank3
R12C,
42±3% for Shank3
R300C; ***P<0.001, 48±3% for
Shank3
Q321R;* P<0.05; Figure 1e). Shank3
STOP was
almost completely absent at the tips of actin filaments
(10±7% for Shank3
STOP; ***P<0.001).
Shank3 binds actin and positively affects actin
polymerization
As Shank proteins and their partners are involved in
actin regulation
13,18,30 and Shank3 colocalizes with
actin fibers, we performed a coimmunoprecipitation
using hippocampal tissue to demonstrate the exis-
tence of Shank3–actin complexes in vivo (Figure 1f).
In addition, we used an actin polymerization assay
to measure and compare the F- to G-actin ratio in
GFP–Shank3- or GFP–C3-transfected cells (Figures 1g
and h). In this assay, RFP–actin was co-transfected
with each construct to stimulate actin polymerization.
We analyzed the Shank3
STOP construct because this
mutated protein does not colocalize with actin
filaments. Overexpression of Shank3
WT significantly
increased the amount of F-actin (1.399±0.039) com-
pared with the control (***P<0.001; Figures 1g and
h), showing the role of Shank3
WT in in vitro actin
polymerization. In contrast, no significant difference
in actin polymerization was observed with
Shank3
STOP protein (0.971±0.062; P>0.05) compared
with the control. These results suggest that the
C terminus of Shank3 is crucial for actin dynamics.
Shank3 mutations affect spine induction and spine
morphology
To analyze the role of Shank3 in actin cytoskeleton
regulation in dendritic spines, we overexpressed the
different constructs in hippocampal neurons and
studied their effects on the organization and shape
of postsynaptic spines. First, we analyzed the sub-
cellular localization of the different Shank3 mutants
co-transfected with an RFP plasmid in hippocampal
neurons. Shank3
WT overexpression led to an accumu-
lation of the protein in dendritic spines (Figure 2a), as
previously reported.
31 Point mutations (Shank3
R12C,
Shank3
R300C and Shank3
Q321R) did not affect this
synaptic targeting. As observed in COS-7 cells,
Shank3
STOP accumulated in the soma, was weakly
localized in the dendrites and was absent from
dendritic spines, indicating that the C terminus was
required for the dendritic targeting of Shank3. These
results are consistent with previous data showing that
the Homer-binding site is involved in the synaptic
localization of Shank3.
22,31
In addition, Shank3
WT significantly increased the
number of spines compared with the control (Figure
2b) and reduced the number of filopodia (Figure 2c)
in rat hippocampal neurons. The number of spines
per 20mm of dendrite length was 6.3±0.4 spines
when Shank3
WT was overexpressed compared with
3.4±0.3 spines in control GFP-positive neurons
(***P<0.001). Overexpression of Shank3
R12C,
Shank3
R300C or Shank3
Q321R also increased the number
of spines, but not as much as Shank3
WT (4.6±0.3,
4.7±0.3 or 5.0±0.2 spines per 20mm, respectively;
**P<0.01 and ***P<0.001 compared with control).
The mutations in the ankyrin domain therefore had
moderate effects on spine induction, but still sig-
nificantly lower than Shank3
WT (1P<0.05; 11P<0.01
and 111P<0.001, respectively). The overexpression of
Shank3
STOP had a stronger effect, with a reduction in
the number of spines compared with Shank3
WT and
with the control (2.6±0.2 spines per 20mm;
111P<0.001 compared with Shank3
WT and *P<0.05
Figure 1 Mutations in Shank3 affect its recruitment to the tips of actin filaments and actin polymerization. (a) Localization
of rare non-synonymous variations or truncating SHANK3 mutations identified in autism spectrum disorder.
6,7 ANK, ankyrin
repeats; Cbs, cortactin-binding site; Hbs, Homer-binding site; PDZ, postsynaptic density 95/discs large/zona occludens-1
homology domain; SAM, sterile alpha motif domain; SH3, Src homology 3 domain. (b) Western blot analysis of the green
fluorescent protein (GFP) constructs expressed in HEK293Tcells. We observed similar sizes of Shank3
WTand fusion proteins
carrying point mutations (Shank3
R12C, Shank3
R300C and Shank3
Q321R). The frameshift mutation results in a truncated protein
(222kDa GFP–Shank3
WT and 169kDa GFP–Shank3
STOP). (c) Localization of Shank3
WT in COS-7 cells transiently transfected
with GFP–Shank3
WT (green) and labeled with phalloidin 647 to visualize F-actin (blue) and with anti-vinculin or anti-
phospho-paxillin (red), two focal adhesion proteins. Shank3
WT is located at the membrane and in intracellular clusters that
colocalize with vinculin or phospho-paxillin at the tips of actin filaments. On the right side, magnification of representative
stress fibers with clusters of Shank3
WT.( d) Localization of Shank3
WT and mutated forms in COS-7 cells. COS-7 cells
transiently transfected with GFP–Shank3
WT or mutated forms (green), and labeled with phalloidin 546 to visualize F-actin
(red) and 40,6-diamidino-2-phenylindole to visualize the nucleus (blue). Shank3
R12C, Shank3
R300C and Shank3
Q321R are located
at the membrane and in intracellular clusters. Conversely, Shank3
STOP is restricted to around the nucleus. (e) Quantification
of the accumulation of GFP constructs at the tips of actin filaments. Percentage of filaments with Shank3 clusters per cell
(%). This accumulation is significantly reduced with mutated Shank3 and absent with Shank3
STOP (n=30–40 cells). Scale
bars represent 15mm. (f) Coimmunoprecipitation of Shank3 and actin in an adult rat brain. Lysate (input) was incubated with
control immunoglobulin or anti-Shank3. Immunoprecipitation was performed, followed by western blotting using anti-b-
actin. (g) Shank3
STOP inhibits the effect of Shank3
WT on actin polymerization. HEK293Twere transiently co-transfected with
red fluorescent protein–actin and GFP–C3 (control), GFP–Shank3
WT or GFP–Shank3
STOP. Representative immunoblots of
G-actin (G) and F-actin (F) fractions obtained with an Actin Polymerization Assay kit. G-actin and F-actin were probed with
anti-actin antibody. (h) Ratio of F-actin/G-actin was measured for each condition. The ratio is normalized to GFP–C3 and is
represented as the mean±s.e.m. Shank3
WT enhances the polymerization of actin (***P<0.001; n=6 independent
experiments). Shank3
STOP inhibits the effect of Shank3 on actin polymerization.
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Molecular Psychiatrycompared with the control). Moreover, a Sh-resistant
form of Shank3
STOP did not rescue the spine pheno-
type in hippocampal neurons where Shank3 was
downregulated (Supplementary Figure 1). Altogether,
our results suggest that Shank3
STOP has a dominant-
negative effect on spine induction in a wild-type
background, probably by affecting the targeting and/
or the stability of the wild-type protein at synapses.
Finally, we investigated the impact of Shank3
mutations on spine maturation and measured spine-
head enlargement and spine length from the base to
the top of the head in rat hippocampal neurons
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Molecular Psychiatrytransfected with each construct (Figure 2d). The
number of spines with head widths >0.5mm was
significantly increased in neurons transfected with
Shank3
WT compared with neurons transfected with
GFP (63±3% of spines >0.5-mm head width com-
pared with 51±3% of spines; *P<0.05; Figures 2e
and f). No difference in spine length was observed
(44±3% of spines >1.0-mm length for the control and
41±3% of spines for Shank3
WT, Figure 2g). Thus, in
mature neurons, Shank3 overexpression promoted
the morphological maturation of spines, as previously
observed with Shank3
WT expressed in aspiny neu-
rons
22 or with Shank1 in hippocampal cells.
21
Compared with the control, Shank3
STOP did not
change the width of spine heads (46.6±2% of spines
>0.5mm; P>0.5) but reduced the length of the spines
(34±2% of spines >1.0-mm length; *P<0.05).
Shank3
Q321R showed a slight increase in the width of
the spine head (59±2% of spines >0.5mm) and a
reduction in spine length (34±2% of spines >1.0mm;
*P<0.05). This suggests that the Q321R mutation
does not abolish the effect of Shank3 on spine
maturation but does affect neck retraction. Finally,
Shank3
R12C and Shank3
R300C did not increase the size
of spine heads (54±4% and 51±3% of spines
>0.5mm; P>0.05 compared with control), suggesting
that these mutations disrupt the effect of Shank3 on
spine morphology. Altogether, our data suggest that
Shank3
WT overexpression promotes spine induction
and maturation, and that all mutations identified in
ASD modify the function of Shank3.
Shank3 mutations affect F-actin content but not
cortactin level in dendritic spines
As actin dynamics have key roles in dendrite
development and specifically in spine formation
and maturation,
32,33 we further examined the effects
of Shank3 mutations on the synaptic levels of F-actin
and cortactin (Figure 3). Cortactin is an F-actin-
binding protein enriched in cell matrix contact sites
that facilitates the nucleation of new actin branches at
the tips of actin filaments. In mature neurons, F-actin
appeared in the form of patches and puncta along the
dendrites, and it was enriched in the heads of
dendritic spines (Figure 3a). We quantified the level
of actin in spine heads as a ratio of the average
intensity of transfected neurons to untransfected
neurons. We observed an increase in F-actin levels
in the spines of Shank3
WT-transfected neurons com-
pared with the control (147±8% for Shank3
WT and
109±6% for the control; **P<0.01; Figure 3b), as
previously described for Shank1.
21 Neurons trans-
fected with Shank3
R12C and Shank3
R300C constructs
displayed intermediate levels of F-actin between the
control and Shank3
WT levels (123±7% for Shank3
R12C
and 125±9% for Shank3
R300C). The absence of an
increase in F-actin as large as that induced by
Shank3
WT suggests that mutations in the ankyrin
domain affect F-actin content in dendritic spines.
Neither the truncating mutation nor Shank3
Q321R
increased F-actin level (93±6% for Shank3
STOP and
115±8% for Shank3
Q321R; 111P<0.001 and 11P<0.05
compared with Shank3
WT). In the case of the truncat-
ing mutation, this was most likely due to a lack of
targeting to the spines. Our data show that enlarge-
ment of dendritic spines induced by Shank3
WT was
correlated with increases in F-actin level. The muta-
tions in the ankyrin domain and the truncated form of
Shank3 all affected spines maturation via an actin-
dependent mechanism, as suggested by our fibroblast
experiments (Figure 1).
As Shank3 binds to cortactin and the loss of
cortactin causes a decrease in spine density,
12,13,21
we examined the effect of each mutation on cortactin
content in dendritic spines. Despite Shank3 muta-
tions significantly reducing the level of F-actin in
spines, cortactin level was not significantly different
between the control and Shank3
WT (Figure 3c;
P>0.05).
The Shank3 mutations decrease spontaneous neuronal
activity
As the number and the morphology of spines might
affect the strength of synaptic transmission, we
Figure 2 Effect of Shank3
WT and mutants on dendritic spine induction and maturation. (a) Hippocampal neurons were
transiently co-transfected with green fluorescent protein (GFP)–Shank3
WT or mutated forms (green) and red fluorescent
protein (red) and processed for immunofluorescence after 4 days (days in vitro 21, DIV21), and the subcellular localization of
each construct was analyzed. Neurons are stained with anti-GFP (green) and anti-DsRED (red). Scale bars represent 20mm.
On the bottom side, magnification of 20mm of the dendrite transfected with each construct. (b) Comparison of spine density
in neurons transfected with the different Shank3 constructs (number of spines per 20mm of dendrite length) in co-transfected
neurons. (c) Comparison of the density of filopodia (number of filopodia per 20mm of dendrite length) in co-transfected
neurons. Shank3
WT leads to an increase in the number of spines and a decrease in the number of filopodia. All mutations
reduce the ability of Shank3 to induce spines. (***P<0.001 and **P<0.01 compared with the control; 111P<0.001, 11P<0.01
and 1P<0.05 compared with Shank3
WT). (d) Examples of spines from neurons transfected with GFP–C3 or GFP–Shank3
WT.
Spine length (green line) and head width (red line) were computed using Volocity software. (e) Truncating mutation causes a
decrease in the number of larger spines and an increase in the number of thin spines. Relative abundance of four different
spine classes according to spine-head size (0–0.25; 0.25–0.5; 0.5–0.75; and >0.75mm). (f) Percentage of spine heads >0.5mm
within the same population. Spine heads are significantly larger in GFP–Shank3
WT- and GFP–Shank3
Q321R-transfected
neurons compared with the control (*P<0.05). Spine heads are significantly smaller in GFP–Shank3
STOP.( g) Percentage of
spines >1.0mm within the same population. Spine length is significantly reduced with GFP–Shank3
Q321R and GFP–
Shank3
STOP constructs compared with the control (*P<0.05; n=17–28 neurons and 1500–1800 spines).
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Shank3 mutations by recording mEPSCs in hippo-
campal neurons. Shank3
WT had no significant
effect on mEPSC amplitude but markedly increased
mEPSC frequency compared with GFP-only neurons
(1.48±0.08 and 0.74±0.08Hz, respectively;
***P<0.001; Figure 4). The present correlation
between Shank3
WT-mediated changes in spine mor-
phology and electrical activity is in agreement with
previous results.
21 Shank3
R12C, Shank3
R300C and
Shank3
Q321R modestly increased mEPSC frequency
but not as much as Shank3
WT (0.98±0.16, 0.97±0.23
and 1.1±0.24Hz, respectively; 1P<0.05). In contrast,
Shank3
STOP strongly reduced the frequency (0.50±
0.17Hz; 111P<0.001) as well as the amplitude of
mEPSCs compared with the control (Shank3
STOP 15.90±
0.72pA, GFP-only 31.49±2.48pA; ***P<0.001), ex-
tending the dominant-negative effect displayed
by Shank3
STOP to the modulation of synaptic trans-
mission.
The Q321R and STOP mutations affect growth cone
motility induced by Shank3
WT
Q321R is a de novo mutation identified in a girl with
autism, language delay and developmental delay.
7
Here, we found that this mutation was associated
with abnormalities in spine morphology (even if less
pronounced than for Shank3
STOP). We then assessed
whether Shank3 could have a role earlier in neuronal
development. Indeed, Shank3 is expressed in the
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Figure 3 Effects of Shank3
WTand mutants on F-actin and cortactin levels in spines. (a) Immunofluorescence microscopy of
hippocampal neurons at DIV21 transiently co-transfected with green fluorescent protein (GFP)–Shank3
WT or mutated forms
and red fluorescent protein. Neurons are stained with anti-GFP and anti-DsRED. F-actin was visualized with phalloidin 647.
Cortactin is visualized with anti-cortactin (blue). Scale bars represent 6mm. (b, c) Quantification of changes in the synaptic
staining intensity of F-actin or cortactin induced by the overexpression of Shank3
WT or the mutated forms. (**P<0.01
compared with the control; 111P<0.001, 11P<0.01 and 1P<0.05 compared with Shank3
WT).
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34 and Shank and cortactin are
enriched within the lamellipodia of motile cells and
in neuronal growth cones.
12,35 We analyzed the
localization of endogenous or overexpressed Shank3
in cultured hippocampal neurons by immunocyto-
chemistry in early stages (Figures 5a and b). Endo-
genous Shank3 was detected in young neurons
(day 2), and labeling with actin revealed the accumu-
lation of the protein in ruffles. We also confirmed the
colocalization of Shank3 and cortactin in axonal
growth cones. Then, we tested whether Shank3
regulated growth cone dynamics by co-transfecting
GFP–C3 with GFP–Shank3
WT or with the mutated
forms in young hippocampal neurons. Four days after
the transfection, live cell imaging was performed, as
described.
28 The axonal growth cone motility was
quantified as a dimensionless motility index. We
quantified the mean value of motility index for 35–67
axonal growth cones for each construct (Figures 5c
and d). We observed an increase of motility index
with Shank3
WT compared with the control
(0.129±0.005 for Shank3
WT to 0.101±0.005 for
GFP–C3; ***P<0.001). This suggests that full-length
Shank3 induces higher axonal growth cone motility.
We did not observe such an increase for GFP–
Shank3
Q321R or GFP–Shank3
STOP (0.106±0.003 and
0.112±0.004; 111P<0.001). Together, these data sug-
gest that these two de novo mutations, Shank3
Q321R
and Shank3
STOP, affect neuronal motility during
development.
Discussion
Three important conclusions can be drawn from this
study. First, we found that Shank3 increases actin
polymerization, promoting spine formation and in-
creasing the frequency of mEPSPs. Second, we
demonstrated that Shank3 mutations identified in
ASD disrupt these processes, providing a cellular
readout for Shank3-associated pathologies. Third, we
described two de novo mutations, Shank3
Q321R and
Shank3
STOP, which were associated with severe loss of
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Figure 4 The Shank3 mutations decreased spontaneous neuronal activity. (a) Miniature EPSCs (mEPSCs) recorded at
 60mV on hippocampal neurons (DIV21) transiently co-transfected with green fluorescent protein (GFP)–C3, GFP–
Shank3
WT or mutated forms. (b) Quantification of mEPSCs frequency and (c) amplitude under different transfection
conditions. In Shank3
WT, there is a significant increase in mEPSC frequency. Each bar of the histogram is the mean±s.e.m. of
10 experiments. ***P<0.001 compared with control; 111P<0.001 and 1P<0.05 compared with Shank3
WT.
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R12C
and Shank3
R300C, which produced an intermediate
phenotype and might represent a risk factor for ASD.
Shank3 promotes spine formation and shape via an
actin-dependent mechanism
Spine structure is regulated by various molecular
mechanisms, and actin polymerization is a crucial
process for synaptic structure and function.
36 Actin
filaments in the spine head are highly dynamic and
regulate the molecular organization of the postsynap-
tic density and modulate postsynaptic signal trans-
duction.
37–39 Our data on neuronal cultures show that
Shank3 overexpression induces an increase in spine
density associated with an F-actin accumulation and
an increase in mEPSP frequency. These effects could
be mediated, in part, by a regulation of capping
proteins, as we demonstrated that Shank3 colocalized
a Shank3 Tij-1 Actin Merge
Shank3 Cortactin Actin Merge
b GFP-C3 MAP2 Actin Merge
MAP2 Actin Merge GFP-Shank3WT
MAP2 Actin Merge GFP-Shank3STOP
Figure 5 Effects of Shank3
WTand mutants on growth cone dynamics. (a) Shank3 is found in the growth cone of neonatal rat-
cultured hippocampal neurons on DIV2. Neurons are labeled for Shank3 (green), F-actin (phalloidin; blue) and either tubulin
(anti-Tuj1; red) or cortactin (anti-cortactin, red). Scale bars represent 20mm. Insets represent high magnifications of the
axonal growth cone. Shank3 colocalized with F-actin (blue) and with cortactin (red) in axonal growth cones. (b) Localization
of Shank3 overexpressed in young neurons. Green fluorescent protein (GFP)–Shank3
WTor Shank3
STOP or GFP–C3 (green) was
transfected in young neurons (DIV0). Immunostaining for MAP2 (red) and actin (phalloidin; blue) revealed that Shank3
WT
accumulates in growth cones, whereas Shank3
STOP is restricted to the cell body. (c) Time-lapse video microscopy of growth
cones from rat hippocampal neurons co-transfected with the control (GFP–C3) and Shank3
WT or mutated forms. Merge
represents three frames with different colors (0min in green, 5min in red and 10min in blue). Scale bars represent 5mm. (d)
Quantification of growth cone motility with the motility index.
28 ***P<0.001 and *P<0.05 compared with the control;
111P<0.001 compared with Shank3
WT.
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stress fibers in fibroblasts. These capping proteins
control the growth of actin filaments in lamellipodia,
resulting in filopodia formation and a reduction in
lamellipodia.
40 In mature neurons, they localize
throughout dendritic spines,
41 similar to Shank3.
Furthermore, the Shank complex could be linked to
several other proteins regulating actin cytoskeleton
dynamics, such as b-Pix, a guanine nucleotide
exchange factor for Rac1 and cdc42 small GTPases;
18
Abp1, a member of the Arp2/3 complex;
17 and
cortactin.
35 Indeed, depletion of the Arp2/3 complex,
including cortactin, Abi2, WAVE–1, N–WASP and
Abp1, alters the morphology and number of
spines.
13,42–45 Altogether, these results suggest that
Shank3 could directly regulate F-actin level in spines,
resulting in a modification of the shape and the
function of these spines.
In this study, we observed increased spine density
and morphology with Shank3, which is consistent
with previous results obtained in aspiny neurons
with Shank3.
22 Shank1B induces an enlargement of
spine heads independently of spine density, and this
enlargement is enhanced by coexpression of the long
form of Homer.
21,43,46 Recent data on Shank1 knock-
out mice suggest that Shank1 is not required for
spine formation but promotes the growth and
stability of large spines, which is consistent with in
vitro results.
47 Shank2 also affects spine head
maturation, depending on the Arp2/3 complex.
30
Therefore, it is now clearly established that
Shank proteins are involved in spinogenesis,
especially in spine maturation, and we highlighted
in this study that this occurs via an actin-dependent
mechanism.
Shank3 mutations associated with ASD disrupt its
cellular functions
We showed that de novo or inherited Shank3
mutations associated with ASD can affect its localiza-
tion at the tip of the F-actin fibers, subsequently
disrupting spine formation and morphology. This
effect was especially strong for Shank3
STOP and was
similar to that observed in hippocampal neurons
where Shank3 was downregulated (this study and
Grabrucker et al.
23) or in cerebellar neurons trans-
fected with Shank3 bearing a mutation in the Homer-
binding site.
22 This mutation appears to have a
dominant-negative effect on the induction and the
maturation of spines in a wild-type background
(Figure 2b). This could be due to interference with
the localization of other binding partners and/or to
PDZ domain dimerization of the mutated form with
the endogenous Shank3.
48
Our results highlight the potential impact of the
two de novo mutations of Shank3 on early stages of
neuronal development. We showed that the endo-
genous as well as the overexpressed Shank3 was
localized in the growth cones of young neurons,
suggesting that Shank3 could participate in neurite
extension. Consistent with this idea, cortactin medi-
ates neurite outgrowth,
13 and the depletion of Abp1,
a linker of Shank3 to the actin complex, results
in increased axon length in early stages of neuronal
development.
49 The Shank3
STOP and Shank3
Q321R
de novo mutations decreased growth cone motility,
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Molecular Psychiatrywhich could lead to disrupted connectivity in
patients carrying either mutation. These results are
consistent with a recent study showing that the lack
of C-terminal domains (including Homer- and cortac-
tin-binding sites, and the SAM domain) inhibits the
induction of neurite outgrowth.
50
Inherited mutations represent risk factors for ASD
Mutations in SHANK3, including de novo mutations,
de novo copy number variations and inherited
mutations, have been frequently reported in pa-
tients.
6,7,50 The importance of the Shank family for
ASD was further strengthened by the recent identifi-
cation of mutations in SHANK2 in ASD patients.
51,52
If the impact of de novo deleterious mutations is well
established, the role of inherited mutations remains
unclear. Here, we showed that the two inherited
mutations, Shank3
R12C and Shank3
R300C, have inter-
mediate effects, mainly on spine formation. These
results suggest that despite their transmission from
healthy parents, these mutations could cause subtle
synaptic defects, increasing the risk of developing
ASD. SHANK3 mutations can also be involved in
other neurological disorders, such as intellectual
disability and schizophrenia.
50 In the case of schizo-
phrenia, the de novo mutation R1117X with germline
mosaicism has been observed in three affected
brothers. They presented mild-to-moderate intellec-
tual disability and schizoaffective disorder, but no
evidence of autistic features. Functional studies have
confirmed that this mutation causes a loss of SHANK3
function in zebrafish and decreases neurite outgrowth
in mice.
50 It is unclear how similar mutations can lead
to different clinical conditions. The same is true not
only for mutations in NLGN3 and NLGN4 described
in autism but also in intellectual disability, Asperger
syndrome and Tourette syndrome with hyperactivity
disorder.
53–55 Mutations in NRXN1 have also been
observed in patients with schizophrenia and in
asymptomatic carriers.
56 These different outcomes
could be due to mutations altering either all or
specific roles of these proteins (for example, axonal
guidance and synapse formation). We can also expect
that additional genetic/epigenetic and environmental
risk factors acting at different levels of brain devel-
opment could bias the phenotype toward different
sets of disorders.
57 The identification of such factors
would allow us to better understand the nature of the
biological mechanisms underlying these different
disorders and to provide insight for new treatments.
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